Featured Studies Results

Study Type: Prevention detection risk | Keyword: BRCA1

Pancreatic Cancer Early Detection for People at High Risk identifier:
NCT04970056 (

Registry and biobank for high risk people undergoing pancreatic cancer screening

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk) identifier:
NCT04251052 (

Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer identifier:
NCT04674306 (

Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.

Men at High Genetic Risk for Prostate Cancer identifier:
NCT03805919 (

Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

MRI Screening in Men at High Risk of Developing Prostate Cancer identifier:
NCT05608694 (

Screening using MRI for men at risk of developing prostate cancer

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation identifier:
NCT04367675 (

People with a BRCA1 or BRCA2 mutation

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study) identifier:
NCT04711109 (

Prevention study enrolling women ages 25-55 with a BRCA1 mutation

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS) identifier:
NCT05129605 (

People at high risk for prostate cancer due to an inherited mutation

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women (TUBA/WISP II) identifier:
NCT05287451 (

Prevention study for women at high risk for ovarian cancer

Blood Markers of Early Pancreas Cancer identifier:
NCT03568630 (

Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer identifier:
NCT05677048 (

People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

Developing a Test for the Detection of Ovarian Cancer identifier:
NCT04794322 (


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation identifier:
NCT02478892 (


Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations identifier:
NCT00823654 (


A Pancreatic Cancer Screening Study for High Risk Individuals identifier:
NCT03250078 (


Pancreatic Cancer Early Detection Program identifier:
NCT02206360 (



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.